1 40 1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.3164/jcbn.16-52" target="_blank" rel="noreferrer noopener">http://doi.org/​10.3164/jcbn.16-52</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Supplementation with carnitine reduces the severity of constipation: A retrospective study of patients with severe motor and intellectual disabilities Publisher An entity responsible for making the resource available Journal of Clinical Biochemistry and Nutrition Date A point or period of time associated with an event in the lifecycle of the resource 2017 Subject The topic of the resource cerebral palsy; enteric feeding; clinical trial; endogenous compound; sex difference; human tissue; intellectual impairment; school child; preschool child; gene expression; medical record review; human; article; child; female; male; controlled study; adult; clinical article; young adult; hospital; middle aged; disease severity; retrospective study; body mass; cholesterol/ec [Endogenous Compound]; infantile spasm; neuronal ceroid lipofuscinosis; clobazam/dt [Drug Therapy]; clonazepam/dt [Drug Therapy]; carnitine; carnitine deficiency/dt [Drug Therapy]; carnitine/dt [Drug Therapy]; constipation; constipation/dt [Drug Therapy]; constipation/pc [Prevention]; diet supplementation; motor dysfunction; 102767-28-2 (levetiracetam); 1069-66-5 (valproic acid); 1309-48-4 (magnesium oxide); 1317-74-4 (magnesium oxide); 14093-02-8 (iron); 14378-32-6 (zinc); 146-22-5 (nitrazepam); 1622-61-3 (clonazepam); 22316-47-8 (clobazam); 298-46-4 (carbamazepine); 461-06-3 (carnitine); 50-06-6 (phenobarbital); 53858-86-9 (iron); 541-15-1 (carnitine); 56-99-5 (carnitine); 57-30-7 (phenobarbital); 57-88-5 (cholesterol); 59-30-3 (folic acid); 6484-89-5 (folic acid); 68291-97-4 (zonisamide); 7439-89-6 (iron); 7440-66-6 (zinc); 7782-49-2 (selenium); 8028-68-0 (phenobarbital); 8047-84-5 (carbamazepine); 84057-84-1 (lamotrigine); 99-66-1 (valproic acid); acute brain disease; albumin; albumin blood level; anticonvulsant therapy; bacterial meningitis; bed rest; brain infarction; carbamazepine/dt [Drug Therapy]; carnitine deficiency; carnitine deficiency/dt [Drug Therapy]; cholesterol blood level; constipation/dt [Drug Therapy]; copper blood level; cupric ion/ec [Endogenous Compound]; enema/dt [Drug Therapy]; epilepsy/dt [Drug Therapy]; folic acid; folic acid blood level; folic acid/ec [Endogenous Compound]; groups by age; iron blood level; iron/ec [Endogenous Compound]; lamotrigine/dt [Drug Therapy]; levetiracetam/dt [Drug Therapy]; magnesium oxide/dt [Drug Therapy]; nitrazepam/dt [Drug Therapy]; Pelizaeus Merzbacher disease; periventricular leukomalacia; phenobarbital/dt [Drug Therapy]; prealbumin; prealbumin/ec [Endogenous Compound]; selenium blood level; selenium/ec [Endogenous Compound]; trace element; tuberous sclerosis; valproic acid; valproic acid/dt [Drug Therapy]; zinc/ec [Endogenous Compound]; zonisamide/dt [Drug Therapy]; constipation; NCL3; Pelizaeus- Merzbacher disease; tuberous sclerosis; West syndrome; pharmacologic intervention; Carnitine Creator An entity primarily responsible for making the resource Murata S; Inoue K; Aomatsu T; Yoden A; Tamai H Description An account of the resource Carnitine is an essential nutrient for the mitochondrial transport of fatty acids. Carnitine deficiency causes a variety of symptoms in multiple organs. Patients with severe motor and intellectual disabilities often have carnitine deficiency. This study aimed to determine the correlation between constipation and carnitine deficiency in them. Patients with severe motor and intellectual disabilities at our hospital were retrospectively reviewed. The correlation between level of free carnitine and severity of constipation was examined. Constipation and non-constipation groups were compared for age; sex; body mass index; bed rest period; use of anti-epileptic drugs, valproate sodium, or enteral nutrition; and serum levels of albumin, pre-albumin, totalcholesterol, free carnitine, folic acid, and trace elements. Moreover, severity of constipation before and after carnitine supplementation was assessed. Twenty-seven patients were enrolled. Of these, 14 were assigned to the constipation group and 13 to the non-constipation group. The free carnitine level was significantly correlated with severity of constipation (R = 0.7604, p<0.01). Free carnitine was significantly lower in the constipation compared with the non-constipation group (p<0.01). No other significant differences between the groups were found. The severity of constipation was significantly relieved after carnitine supplementation (p<0.001). In conclusion, carnitine supplementation could reduce the severity of constipation. Copyright © 2017 JCBN. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.3164/jcbn.16-52" target="_blank" rel="noreferrer noopener">10.3164/jcbn.16-52</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). 102767-28-2 (levetiracetam) 1069-66-5 (valproic acid) 1309-48-4 (magnesium oxide) 1317-74-4 (magnesium oxide) 14093-02-8 (iron) 14378-32-6 (zinc) 146-22-5 (nitrazepam) 1622-61-3 (clonazepam) 2017 22316-47-8 (clobazam) 298-46-4 (carbamazepine) 461-06-3 (carnitine) 50-06-6 (phenobarbital) 53858-86-9 (iron) 541-15-1 (carnitine) 56-99-5 (carnitine) 57-30-7 (phenobarbital) 57-88-5 (cholesterol) 59-30-3 (folic acid) 6484-89-5 (folic acid) 68291-97-4 (zonisamide) 7439-89-6 (iron) 7440-66-6 (zinc) 7782-49-2 (selenium) 8028-68-0 (phenobarbital) 8047-84-5 (carbamazepine) 84057-84-1 (lamotrigine) 99-66-1 (valproic acid) acute brain disease Adult albumin albumin blood level anticonvulsant therapy Aomatsu T Article bacterial meningitis bed rest body mass brain infarction carbamazepine/dt [Drug Therapy] carnitine carnitine deficiency carnitine deficiency/dt [Drug Therapy] carnitine/dt [Drug Therapy] Cerebral Palsy Child cholesterol blood level cholesterol/ec [Endogenous Compound] Clinical Article Clinical Trial clobazam/dt [Drug Therapy] clonazepam/dt [Drug Therapy] Constipation constipation/dt [Drug Therapy] constipation/pc [Prevention] Controlled Study copper blood level cupric ion/ec [Endogenous Compound] diet supplementation Disease Severity Endogenous Compound enema/dt [Drug Therapy] enteric feeding epilepsy/dt [Drug Therapy] Female folic acid folic acid blood level folic acid/ec [Endogenous Compound] Gene Expression groups by age Hospital Human Human Tissue infantile spasm Inoue K Intellectual Impairment iron blood level iron/ec [Endogenous Compound] Journal of Clinical Biochemistry and Nutrition lamotrigine/dt [Drug Therapy] levetiracetam/dt [Drug Therapy] magnesium oxide/dt [Drug Therapy] Male Medical Record Review Middle Aged motor dysfunction Murata S NCL3 neuronal ceroid lipofuscinosis nitrazepam/dt [Drug Therapy] Pelizaeus Merzbacher disease Pelizaeus- Merzbacher disease periventricular leukomalacia pharmacologic intervention phenobarbital/dt [Drug Therapy] prealbumin prealbumin/ec [Endogenous Compound] Preschool Child Retrospective Study School Child selenium blood level selenium/ec [Endogenous Compound] sex difference Tamai H trace element Tuberous Sclerosis valproic acid valproic acid/dt [Drug Therapy] West syndrome Yoden A Young Adult zinc/ec [Endogenous Compound] zonisamide/dt [Drug Therapy]